Cargando…

Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments

BACKGROUND: Despite extensive clinical use, the mechanisms that lead to therapeutic resistance to anti-programmed cell-death (PD)-1 monoclonal antibodies (mAbs) remain elusive. Here, we sought to determine how interactions between the Fc region of anti-PD-1 mAbs and Fcγ receptors (FcγRs) affect ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreno-Vicente, Julia, Willoughby, Jane E, Taylor, Martin C, Booth, Steven G, English, Vikki L, Williams, Emily L, Penfold, Christine A, Mockridge, C Ian, Inzhelevskaya, Tatyana, Kim, Jinny, Chan, H T Claude, Cragg, Mark S, Gray, Juliet C, Beers, Stephen A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Basic Tumor Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753441/ https://www.ncbi.nlm.nih.gov/pubmed/35017153 http://dx.doi.org/10.1136/jitc-2021-003735

Ejemplares similares

Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering
por: Heckel, Franziska, et al.
Publicado: (2022)

Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
por: Yu, Xiaojie, et al.
Publicado: (2020)

FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion
por: Oldham, Robert J, et al.
Publicado: (2020)

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms
por: Simpson, Alexander P., et al.
Publicado: (2022)

Domain binding and isotype dictate the activity of anti-human OX40 antibodies
por: Griffiths, Jordana, et al.
Publicado: (2020)

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity
por: Yu, Xiaojie, et al.
Publicado: (2021)

Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc
por: Dadas, Osman, et al.
Publicado: (2023)

Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
por: Stopforth, Richard J., et al.
Publicado: (2016)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

SUN-135 Characterization of Transcription Factor Immunostaining and Null Cell Adenoma Status in Hormone Negative Pituitary Adenomas
por: Baertsch, Hans C, et al.
Publicado: (2020)

Immune characterization of pre-clinical murine models of neuroblastoma
por: Webb, Emily R., et al.
Publicado: (2020)

SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease
por: Risbridger, Gail, et al.
Publicado: (2019)

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
por: Schoenfeld, A.J., et al.
Publicado: (2019)

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
por: Liu, Rena, et al.
Publicado: (2020)

Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
por: Renga, Giorgia, et al.
Publicado: (2022)

SAT-141 Glycoprotein NMB (GPNMB) Is Pro-Tumorigenic in TSC2-Null Cancer Cells and Is a Potential Drug Target and Biomarker for Lymphangioleiomyomatosis (LAM)
por: Gibbons, Erin, et al.
Publicado: (2020)

Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy
por: Lu, Chia-Sing, et al.
Publicado: (2020)

Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
por: Peng, Zhi-Peng, et al.
Publicado: (2023)

Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8(+) T cells
por: Dwyer, Connor J., et al.
Publicado: (2020)

Gallic acid induces T-helper-1-like T(reg) cells and strengthens immune checkpoint blockade efficacy
por: Deng, Biaolong, et al.
Publicado: (2022)

Cancer-Associated Fibroblasts Suppress CD8(+) T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade
por: Jenkins, Liam, et al.
Publicado: (2022)

ODP571 Blockade of ErbB-2 Nuclear Function Induces the Interferon Signaling Pathway in Breast Cancer Models Resistant to Trastuzumab
por: Elizalde, Patricia V, et al.
Publicado: (2022)

Cyclophosphamide depletes tumor infiltrating T regulatory cells and combined with anti-PD-1 therapy improves survival in murine neuroblastoma
por: Webb, Emily R., et al.
Publicado: (2022)

THU534 Humoral Hypercalcemia Of Malignancy As Initial Presentation Of Hepatocellular Carcinoma And Monoclonal Gammopathy Of Undetermined Significance
por: Jovanovic, Filip, et al.
Publicado: (2023)

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
por: McAuliffe, James, et al.
Publicado: (2021)

SUN-LB056 The Pharmacological Blockade of the Splicing Factor SF3B1 Exerts Antitumor Actions in Different Endocrine-Related Cancers
por: Gahete, Manuel, et al.
Publicado: (2019)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
por: Hubert, Pascale, et al.
Publicado: (2021)

Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?
por: Wong, Hilda, et al.
Publicado: (2012)

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
por: White, Ann L., et al.
Publicado: (2015)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Computer-assisted surgery in orthopedic oncology: Technique, indications, and a descriptive study of 130 cases
por: Gerbers, Jasper G, et al.
Publicado: (2014)

Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy
por: Liu, Xia, et al.
Publicado: (2022)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
por: Turaj, Anna H., et al.
Publicado: (2018)

The Scandinavian Sarcoma Group Central Register: 6,000 patients after 25 years of monitoring of referral and treatment of extremity and trunk wall soft-tissue sarcoma
por: Trovik, Clement, et al.
Publicado: (2017)

Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
por: Nagaoka, Koji, et al.
Publicado: (2020)

Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
por: Aoyama, Shota, et al.
Publicado: (2021)

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors
por: Hao, Xingxing, et al.
Publicado: (2021)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
por: Liu, Liming
Publicado: (2017)

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
por: Lee, Ju Yeon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ebf1m977me3mpe1t0c4ssmmkk9